Do you want to read an article? Please log in or register.
LBA2: ETOP-Roche i-TIMES: Late administration is non-inferior to early administration of immune checkpoint inhibitors in lung cancer
Lung, Respiratory and Thoracic Cancer
ELCC 2026
Related content
Lung, Respiratory and Thoracic Cancer
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1
Lung Cancer
Murata D, Azuma K, Murotani K, Ito K, Nomizo T, Yamada K, Imabayashi T, Iwanaga K, Chibana K, Ota T, Nishii Y, Nakao A, Okada A, Hamai K, Tanimura K, Yoshimine K, Tamura Y, Takaki R, Goto Y, Hibino M, Oba T, Sumi T, Kaneda H, Nishioka N, Yamada T, Takayama K
doi: 10.1016/j.lungcan.2025.108772
Lung, Respiratory and Thoracic Cancer
Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis
Lung Cancer
Zhang Y, Zhao J, Ma Z, Yi J, Yuan Y, Lang L, Zhang C, Zhu M, Zhang Y
doi: 10.1016/j.lungcan.2025.108700
Lung, Respiratory and Thoracic Cancer
Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data
Lung Cancer
Gemelli M, Cortinovis D, Carola G, Moretti L, Piazza F, Calza S, Ricotta R, Grisanti S, Rota M
doi: 10.1016/j.lungcan.2025.108621
Lung, Respiratory and Thoracic Cancer
Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis
Semin Oncol
Ganatra N, Thompson J, Desai R, Doshi J, Jain P, Pasnoor DS, Jain A
doi: 10.1016/j.seminoncol.2025.152431
Lung, Respiratory and Thoracic Cancer
Immune-inflammatory predictors of early and brain recurrence in young patients with resected non-small cell lung cancer
Lung Cancer
Brascia D, Mangiameli G, Congedo MT, Mastromarino MG, Catelli C, Schiavon M, Giudici V, Senatore A, Bonis A, Lucchi M, Luzzi L, Magaritora S, Rea F, Marulli G
doi: 10.1016/j.lungcan.2026.108946
Lung, Respiratory and Thoracic Cancer
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group
Lung Cancer
Brandão M, Prisciandaro E, Xenophontos E, Mariolo A, Sadeghi AH, Filippi AR, Levy A, Bandura A, Caramella C, Dickhoff C, de Margerie-Mellon C, Faivre-Finn C, Portik D, Sanchez-Lorente D, De Ruysscher D, Smit E, Gobbini E, Fadel E, Ruffini E, Olmetto E, Cortiula F, Bahce I, Houda I, Opitz I, Naidoo J, Edwards J, Remon J, Benitez JC, Trujillo JC, Derks J, Amrane K, Hartemink KJ, Stathopoulos K, Hendriks LEL, Iglesias M, Occhipinti M, Guckenberger M, Giaj Levra N, Girard N, Reguart N, Mercier O, Bironzo P, Hofman P, Petersen RH, De Angelis R, Abgral R, Terrisse S, Popat S, Pierret T, Blum TG, Ricardi U, Dionisi V, Berghmans T, Dingemans AC, European Organisation for Research, Treatment of Cancer EORTC Lung Cancer Group
doi: 10.1016/j.lungcan.2025.108798
Lung, Respiratory and Thoracic CancerCOVID-19
Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor
Lung Cancer
Iso H, Ariyasu R, Fujishima S, Ito M, Nibuya K, Sugai M, Tsugitomi R, Amino Y, Uchibori K, Yanagitani N, Ninomiya H, Seike M, Nishio M
doi: 10.1016/j.lungcan.2025.108631
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Xenophontos E, Giaj Levra N, Durieux V, van Geffen WH, Grisay G, De la Pinta Alonso C, Arasanz H, Prisciandaro E, Ferrara R, Derks J, Von der Thusen J, Dickhoff C, Brandão M, Faivre-Finn C, Edwards J, Ruysscher D, Remon J, Dingemans AC, Berghmans T
doi: 10.1016/j.lungcan.2025.108671
Lung, Respiratory and Thoracic Cancer
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
Lung Cancer
Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL
doi: 10.1016/j.lungcan.2026.109385